Aslan Pharmaceuticals (ASLN) has released an update.
ASLAN Pharmaceuticals is set to adjust its ADS (American Depositary Shares) ratio, effectively executing a one-for-eight reverse ADS split, without altering ordinary shares, effective July 3, 2024. The change is anticipated to proportionally increase the ADS trading price on the Nasdaq, though the company notes this outcome is not guaranteed. ASLAN specializes in developing innovative immunology-focused treatments, including eblasakimab for atopic dermatitis and farudodstat for alopecia areata, with key trial results expected in 2024.
For further insights into ASLN stock, check out TipRanks’ Stock Analysis page.
